Riskpilot← Back to searchSign inGet full accessPharmability AB
ABActiveOrg 5591490213Alviksvägen 1Research and experimental development on natural sciences and engineering · NACE 7210Est. 20181 employees
Revenue 2024
SEK 0
EBITDA margin
—
+73% vs 2023
Equity ratio
13.1%
Financial strength
Net profit 2024
SEK -2,7M
+70% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -2,3M | +73% |
| Net profit | SEK -2,7M | +70% |
| Total assets | SEK 12,9M | +379% |
| Equity | SEK 1,7M | -31% |
| Employees | 1 | — |
Legal name
Pharmability AB
Org number
5591490213
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
13 februari 2018
Share capital
SEK 95 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget ska utveckla läkemedel mot infektioner och inflammatoriska sjukdomar samt med därmed förenlig verksamhet.
Address
Alviksvägen 1
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — | — | — |
| EBITDA | −99 | 112 | −195 | −2 510 | −2 362 | −8 328 | −2 287 |
| Depreciation & amort. | −0 | −86 | −169 | −355 | −407 | −398 | −355 |
| EBIT | −99 | 26 | −364 | −2 865 | −2 769 | −8 726 | −2 642 |
| Net financials | — | — | −2 | — | −1 | 2 | −11 |
| Profit before tax | −99 | 26 | −366 | −2 865 | −2 770 | −8 724 | −2 653 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | −99 | 26 | −366 | −2 865 | −2 770 | −8 724 | −2 653 |
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Total assets | 523 | 619 | 5 889 | 8 069 | 5 257 | 2 685 | 12 862 |
| Equity | −49 | 545 | 5 385 | 7 930 | 5 160 | 2 436 | 1 687 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 247 |
| Short-term debt | 572 | 75 | 504 | 139 | 96 | 249 | 10 929 |
| Total debt | 572 | 75 | 504 | 139 | 96 | 249 | 11 176 |
EBITDA margin
-228700000.0%
This company
15.8%
Market median
-1447468454% vs market
20182024
Equity ratio
13.1%
This company
38.2%
Market median
-66% vs market
20182024
Return on equity
-157.3%
This company
18.4%
Market median
-955% vs market
20182024
Net profit margin
-265300000.0%
This company
8.1%
Market median
-3275308742% vs market
20182024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20182024
Debt / equity
6.62×
This company
0.62×
Market median
-968% vs market
20182024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-02-01 – 2018-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
CR | Audit | 2024 | — | — |
LJ | Audit | 2021 | — | — |
LM Chief Executive Officer | Chief Executive Officer | 2021 | — | — |
PC Auditor Substitute | Auditor Substitute | 2024 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Deputy Board Member | 2021 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2025 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Chairman | 2021 | — | — | |
| Board of Directors | 2025 | — | — | |
| Board of Directors | 2024 | — | — | |
| Board of Directors | 2021 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Pharmability AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Carl-Wilhelm Robin Ericsson | Audit | 0 companies |
| Leif Johan Christer Lüsch | Audit | 0 companies |
| Leo Magnus Holmgren | Chief Executive Officer | 0 companies |
| Pia Caroline Ståhle | Auditor Substitute | 0 companies |
| Ludwig Magnus Holmgren | Deputy Board Member | 0 companies |
| Ellen Mona Gratia Wilcke | Board of Directors | 0 companies |
| Pirkko Vilja Päivikki Tamsen | Board of Directors | 0 companies |
| Peder Sven Walberg | Board of Directors | 0 companies |
| Maria Elisabet Tell | Board of Directors | 0 companies |
| Anna-Lena Marie Spetz | Board of Directors | 0 companies |
| John Erik Andersson Moll | Board of Directors | 0 companies |
| Jan-Erik Nyström | Chairman | 0 companies |
| Carl Christian Krog-Jensen | Board of Directors | 0 companies |
| Gustav Evert Notander | Board of Directors | 0 companies |
| Stina Elna Josefin Wallmark | Board of Directors | 0 companies |